ASPR's IBx Portfolio
Product: Hyper-Immune Plasma Yield
Description of Project: Plasma Technologies was contracted to develop and optimize a process to produce higher yielding anti-COVID-19 immune serum for scale-up and manufacturing.
Unique Impact: If successful, a higher yield hyperimmune serum would be an improvement over the current standard method. Convalescent plasma, which is collected from a person who has recovered from a disease, may be beneficial in the treatment of patients suffering from COVID-19.
Base Award Amount: $741,925.00
Category: Therapeutics Supplies and Raw Materials